Metabolic & GLP-1

1. Metabolic & GLP-1well supported · human dataAdded 8 October 2026

   High triglyceride-glucose scores tracked with up to 45% higher heart risk

   In adults with early-stage cardio-kidney-metabolic syndrome, those with the highest triglyceride-glucose index scores had up to 45% higher risk of developing cardiovascular disease than those with the lowest, in pooled data from nine studies that followed people over time.

   ⚠What it shows: A consistent link, not proof of cause: it pools nine studies that followed people rather than testing anything on them, and the studies disagreed with each other quite a bit. The populations studied were not very diverse, so the picture may differ elsewhere.Meta-analysis · BMC Cardiovasc Disord

   Full breakdown →Metabolic syndrome explained →Heart Age Calculator →Association between triglyceride-glucose-related indices and cardiovascular disease risk in population with cardio-kidney-metabolic syndrome stages 0-3: a systematic review and meta-analysis. BMC Cardiovasc Disord 2026
2. Metabolic & GLP-1preliminary · human dataAdded 8 October 2026

   Oral PCSK9 pills cut LDL cholesterol by up to 61.8 points in trials

   Across five randomised trials in 4,227 people with high cholesterol, oral PCSK9 inhibitor pills lowered LDL cholesterol by as much as 61.8 percentage points more than placebo, with higher doses doing more and no short-term safety signal. Which pill or dose is best remains uncertain.

   ⚠What it shows: Big effects but early days: results pooled from five trials in 4,227 people show large LDL drops against placebo, yet nearly all pill-versus-pill comparisons were indirect and the authors rate the overall certainty as low. Safety was only tracked over the short term.Meta-analysis · Endocrine

   Full breakdown →ApoB explained →Heart Age Calculator →Comparative efficacy and safety of orally administered PCSK9 inhibitors in patients with Hypercholesterolaemia: a dose-stratified systematic review and network meta-analysis. Endocrine 2026
3. Metabolic & GLP-1preliminary · human dataAdded 6 October 2026

   Every exercise type improves insulin resistance, but HIIT ranks top

   In a network meta-analysis of 86 randomised trials covering 4358 adults with overweight or obesity, every exercise modality improved insulin-resistance markers versus usual care, with HIIT ranking highest and benefits peaking around 1000-1200 MET-minutes per week. Adding calorie restriction to exercise showed no significant extra benefit for these markers.

   ⚠What it shows: Strong on the big picture, softer on the rankings: results pooled from 86 trials in 4358 adults with overweight or obesity. The certainty was rated low to moderate, and HIIT's top spot relies partly on indirect comparisons that still need head-to-head trials.Study · Diabetes Obes Metab

   Full breakdown →Insulin sensitivity explained →Heart Rate Zone Calculator →Exercise and Insulin-Resistance Biomarkers in Adults With Overweight/Obesity: A Network Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab 2026
4. Metabolic & GLP-1well supported · human dataAdded 4 October 2026

   Both weights and cardio blunt the post-meal blood sugar spike

   Across pooled trials in 1,401 adults with overweight or obesity and cardiometabolic disorders, exercise training lowered post-meal blood glucose and insulin, and the effect held regardless of age, BMI, baseline glucose levels or how often and how long people trained.

   ⚠What it shows: Consistent but modest in size: results pooled from 29 trials in 1,401 adults who were overweight or living with cardiometabolic problems, so the findings may not read across to lean, healthy people. Post-meal glucose fell with both weights and cardio, while insulin only clearly fell with cardio.Meta-analysis · Diabetes Res Clin Pract

   Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →The effects of exercise training on postprandial glycemia and insulinemia in adults with overweight or obesity and with cardiometabolic disorders: A systematic review and meta-analysis. Diabetes Res Clin Pract 2023
5. Metabolic & GLP-1preliminary · human dataAdded 2 October 2026

   Sprint intervals match steady cardio for metabolic health

   Pooled results from 40 randomised trials in 1,460 people show sprint interval training improved blood sugar, insulin and cholesterol markers compared with no exercise, and performed broadly on par with moderate continuous cardio.

   ⚠What it shows: Promising but shaky: results pooled from 40 trials in 1,460 people pointed the same way, yet the trials disagreed with each other and some results shifted when single studies were removed. The authors themselves rated the certainty of the evidence as low to very low.Review · J Sports Sci

   Full breakdown →HIIT explained →Metabolic Fitness Index →Effects of sprint interval training on markers of metabolic health: A three-level meta-analysis of randomised controlled trials. J Sports Sci 2026
6. Metabolic & GLP-1preliminary · human dataAdded 1 October 2026

   Time-restricted eating may trim HbA1c in type 2 diabetes, but the evidence is shaky

   Pooled results from 13 trials in 544 people with type 2 diabetes link time-restricted eating to a 0.46 percentage point drop in HbA1c and a smaller waist. The authors rate the evidence as fragile and hypothesis-generating, with no effect found on sleep, lipids or blood pressure.

   ⚠What it shows: Treat this as a hint rather than a verdict: the 13 trials were small, they disagreed sharply with each other, and the authors themselves call the pooled results hypothesis-generating. One headline result, a drop in body mass index, vanished entirely when a single trial was removed.Systematic review · Front Nutr

   Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Effects of time-restricted eating on metabolic panel and sleep profile in patients with type 2 diabetes: a meta-analysis. Front Nutr 2026
7. Metabolic & GLP-1well supported · human dataAdded 28 September 2026

   Intermittent fasting's diabetes benefits vanish when the fasting stops

   In pooled trial data from people with type 2 diabetes, intermittent fasting lowered HbA1c, fasting glucose and body weight over the short term (under 3 months) compared with other diets, but performed no better in the long term and the metabolic benefits disappeared once the fasting stopped.

   ⚠What it shows: A fair verdict on durability: results pooled from 12 trials with 966 people with type 2 diabetes, though the studies disagreed with each other a fair amount, so treat the exact effect sizes loosely. The long-term data showed no advantage over other diets, and the gains vanished after people stopped fasting.Meta-analysis · Nutr Res

   Full breakdown →Insulin sensitivity explained →Calorie Deficit Calculator →The metabolic effects of intermittent fasting in patients with type 2 diabetes exist in the short term but disappear after its discontinuation: A systematic review and meta-analysis of randomized controlled trials. Nutr Res 2025
8. Metabolic & GLP-1well supported · human dataAdded 23 September 2026

   Probiotics nudged blood sugar down in type 2 diabetes

   Pooled results from nine placebo-controlled trials in 649 people with type 2 diabetes found that probiotic supplements taken alongside standard treatment significantly reduced fasting glucose, cut HbA1c by 0.42 points on average, and lowered insulin levels.

   ⚠What it shows: Promising and unusually consistent: results pooled from nine placebo-controlled trials in 649 people with type 2 diabetes, and the trials agreed closely with one another. The evidence base is still small, and probiotics were only ever tested as an add-on to standard care, never a replacement.Meta-analysis · Endocr Metab Immune Disord Drug Targets

   Full breakdown →Insulin sensitivity explained →Probiotic Supplementation and its Potential Benefits in Type 2 Diabetes: A Meta-analysis. Endocr Metab Immune Disord Drug Targets 2026
9. Metabolic & GLP-1well supported · human dataAdded 19 September 2026

   Semaglutide linked to more benign growths, not cancer, in diabetes trials

   In pooled data from 19 randomised trials covering 38,160 adults with type 2 diabetes, semaglutide was associated with 19% higher odds of developing any neoplasm and 28% higher odds of benign growths. The link with malignant tumours was not statistically significant.

   ⚠What it shows: Solid as drug evidence goes: results pooled from 19 trials in 38,160 adults with type 2 diabetes, and the extra risk showed up mainly in benign growths, with the apparent link to cancer small enough that chance cannot be ruled out. Trials ran at most 156 weeks, so risk over decades remains unknown.Systematic review · Front Pharmacol

   Full breakdown →GLP-1 explained →Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2026
10. Metabolic & GLP-1well supported · human dataAdded 16 September 2026

    Frequent sitting breaks tame blood sugar; harder ones tackle blood fats

    Pooled results from 144 randomised studies in 2216 adults suggest the best way to break up sitting depends on the goal: frequent activity bouts did most for blood glucose, longer or more intense bouts were needed to lower triglycerides, and moderate to vigorous intensity improved blood vessel function. Activity breaks also lowered insulin and both systolic and diastolic blood pressure in these short-term experiments.

    ⚠What it shows: Convincing for the hours after you move, unproven for the years ahead: results pooled from 144 short lab experiments covering 2216 adults, so whether these acute improvements add up to lasting health benefits was not tested here.Meta-analysis · Eur J Prev Cardiol

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Optimizing physical activity bouts to interrupt sedentary behaviour for cardiometabolic health: a systematic review and meta-analyses of randomized controlled trials. Eur J Prev Cardiol 2026
11. Metabolic & GLP-1preliminary · human dataAdded 15 September 2026

    Yoga and meditation outdid conventional exercise on diabetes markers, on shaky evidence

    In pooled comparisons of randomised trials in people with type 2 diabetes, mind-body exercise outperformed conventional exercise on several cardiometabolic markers: mindfulness-based training lowered HbA1c by 0.78 points and systolic blood pressure by 13.00 mmHg, though most comparisons were rated very low certainty.

    ⚠What it shows: Handle with care: although this pools randomised trials, the reviewers themselves rated most comparisons very low certainty because of bias inside the trials and disagreement between them. The trials were also short, so the strikingly large effects need confirming before anyone reshuffles their routine.Meta-analysis · BMC Cardiovasc Disord

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Comparative efficacy of various mind-body exercise types on cardiometabolic health in patients with type 2 diabetes: a network meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2025
12. Metabolic & GLP-1preliminary · human dataAdded 14 September 2026

    Diet plus exercise helps the heart even when the scale barely moves

    An umbrella review covering 112 systematic reviews and 2332 randomised trials found all lifestyle approaches produced modest weight loss in adults with overweight or obesity, with combined diet and physical activity delivering the largest reduction beyond a year at 3.68 kg, and cardiometabolic benefits that were partly independent of the weight lost.

    ⚠What it shows: The broad picture is trustworthy, the exact numbers less so: 112 pooled reviews covering 2332 trials agreed that lifestyle change works modestly, but the reviews often disagreed with each other and 69% were rated low or critically low quality. The headline weight figure beyond a year rests on a single contributing review.Study · Obes Pillars

    Full breakdown →Energy balance explained →Calorie Deficit Calculator →Effectiveness of dietary, physical activity, and lifestyle interventions on weight and cardiometabolic outcomes in adults with overweight or obesity: an umbrella review of 112 systematic reviews and meta-analyses from 50 countries. Obes Pillars 2026
13. Metabolic & GLP-1well supported · human dataAdded 12 September 2026

    Lifestyle change cut diabetes risk sharply, but the effect faded once programmes ended

    In a systematic review of seven randomised trials covering 5663 people with impaired glucose tolerance, lifestyle programmes cut the risk of developing diabetes, with relative risk reductions of 25% to 65% across trials. The protection tended to fade once the programmes ended, and the one trial that tracked deaths found no difference.

    ⚠What it shows: About as solid as prevention evidence gets on the headline effect: seven trials in 5663 high-risk people followed for three to six years. The programmes varied widely, the benefit shrank once they ended, and the single trial that tracked deaths found no difference.Meta-analysis · Metabolism

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: a systematic review of randomized controlled trials. Metabolism 2013
14. Metabolic & GLP-1well supported · human dataAdded 12 September 2026

    Cardio plus weights beats any single workout for blood pressure in sedentary adults

    A network meta-analysis of 47 randomised trials in 2,355 sedentary adults found combined aerobic plus strength training beat any single exercise type for lowering blood pressure, while HIIT ranked best for cutting total cholesterol and Tai Chi topped the rankings for LDL cholesterol and glycated haemoglobin.

    ⚠What it shows: Solid as a broad map, less so on the fine print: pooled results from 47 trials in 2,355 sedentary adults, most judged at low risk of bias. The 'best exercise' rankings lean partly on comparisons between trials that never faced each other head to head, so treat them as a guide rather than a final league table.Meta-analysis · Endocrine

    Full breakdown →HIIT explained →Metabolic Fitness Index →Effects of different training protocols on physiological indicators and cardiovascular risk factors of sedentary adults: a systematic review and network meta-analysis of randomised controlled trials. Endocrine 2026
15. Metabolic & GLP-1well supported · human dataAdded 8 September 2026

    The oral GLP-1 pill orforglipron hits the gut hard at higher doses

    Pooled data from randomised trials of orforglipron, an oral GLP-1 pill, show gut side effects climb with dose over 26 weeks: at 45 mg the odds of nausea and of vomiting were more than 11 times those on placebo, and the odds of quitting over gut symptoms were about 10 times higher, yet no dose raised pancreatitis risk.

    ⚠What it shows: Solid on side effects but only over 26 weeks: pooled results from placebo-controlled trials across five doses in adults with and without type 2 diabetes. Longer-term safety, and how the pill compares directly with injectable GLP-1 drugs, remain open questions.Meta-analysis · Endocrinol Diabetes Metab

    Full breakdown →GLP-1 explained →The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials. Endocrinol Diabetes Metab 2026
16. Metabolic & GLP-1well supported · human dataAdded 7 September 2026

    Probiotics nudge blood sugar in the right direction across 47,720 trial participants

    Pooling 47 meta-analyses of randomised trials covering 47,720 people, probiotic and synbiotic supplements delivered significant reductions in fasting glucose, fasting insulin, insulin resistance and long-term blood sugar (HbA1c), with the clearest benefit in people whose glucose control was already impaired.

    ⚠What it shows: As broad as nutrition evidence gets: results pooled from 47 separate pooled analyses covering 47,720 trial participants, with the clearest benefit in people whose blood sugar control was already impaired. The underlying analyses disagreed with each other a fair amount, and two authors work for a major food and drinks company.Systematic review · Crit Rev Food Sci Nutr

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Role of probiotics/synbiotic supplementation in glycemic control: A critical umbrella review of meta-analyses of randomized controlled trials. Crit Rev Food Sci Nutr 2024
17. Metabolic & GLP-1well supported · human dataAdded 6 September 2026

    Cardio after eating lowers blood sugar and insulin, fasted cardio does not

    Pooled results from 51 crossover studies in healthy adults show a single bout of continuous aerobic exercise lasting at least 30 minutes lowered insulin, raised glucagon, and lowered blood glucose only when performed after a meal, not in the fasted state.

    ⚠What it shows: Solid but with a wide spread: results pooled from 51 small studies in healthy adults, fewer than 400 people per outcome, and the studies disagreed with each other a lot, so the exact size of the drop is uncertain. The glucagon finding rests on just 5 studies and 47 people.Meta-analysis · Sports Med

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →The Effect of a Single Bout of Continuous Aerobic Exercise on Glucose, Insulin and Glucagon Concentrations Compared to Resting Conditions in Healthy Adults: A Systematic Review, Meta-Analysis and Meta-Regression. Sports Med 2021
18. Metabolic & GLP-1preliminary · human dataAdded 5 September 2026

    Next generation weight loss drugs leave the original GLP-1s behind

    In a network meta-analysis of 58 trials covering 24 214 adults with overweight or obesity but without diabetes, next generation incretin drugs outperformed conventional GLP-1 agonists for weight loss: retatrutide cut body weight by 22.10% versus placebo, tirzepatide by 19.28% and CagriSema by 17.32%.

    ⚠What it shows: Strong evidence overall, pooling 58 trials of 24 214 adults, but few of these drugs have been tested against each other directly, so the rankings rest partly on indirect comparisons. The tolerability findings, including more people stopping retatrutide and danuglipron, were rated low certainty.Study · BMJ Med

    Full breakdown →Energy balance explained →Calorie Deficit Calculator →Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. BMJ Med 2026
19. Metabolic & GLP-1well supported · human dataAdded 3 September 2026

    Weight-loss jabs show no link to suicidal behaviour across 25 trials

    Across 25 randomised controlled trials, people taking GLP-1 receptor agonists such as semaglutide and liraglutide showed no higher rates of suicidal behaviour than controls, and the null held for suicidal ideation, attempts and completed suicides alike.

    ⚠What it shows: About as reassuring as trial evidence gets: results pooled from 25 trials where people were assigned at random showed no rise in any form of suicidal behaviour, on any of the drugs, and the trials did not disagree with each other. Suicidal behaviour is rare, though, so very small effects in specific groups cannot be fully ruled out.Meta-analysis · J Diabetes

    Full breakdown →Metabolic syndrome explained →Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials. J Diabetes 2025
20. Metabolic & GLP-1well supported · human dataAdded 2 September 2026

    'Healthy obesity' is not risk-free, but fitness may explain the gap

    People with so-called metabolically healthy obesity move more, sit less and are fitter than those with unhealthy obesity, yet pooled cohort data still show a 24-33% higher risk of death and cardiovascular disease compared with metabolically healthy normal-weight people. The one study to test cardiorespiratory fitness directly suggests fitness differences may largely explain that gap.

    ⚠What it shows: Strong as summaries go but not proof: it pools dozens of studies that followed people rather than testing anything on them, so it cannot show cause, and the extra death risk sat on the edge of significance. Only a single study examined whether fitness explains the difference.Systematic review · Prog Cardiovasc Dis

    Full breakdown →All-cause mortality explained →VO2max Calculator →Role of Physical Activity and Fitness in the Characterization and Prognosis of the Metabolically Healthy Obesity Phenotype: A Systematic Review and Meta-analysis. Prog Cardiovasc Dis 2018
21. Metabolic & GLP-1well supported · human dataAdded 2 September 2026

    Weekly semaglutide beats daily liraglutide for weight loss

    In a pooled analysis of three randomised trials with 922 adults, once-weekly semaglutide produced significantly greater reductions in body weight, HbA1c and fasting plasma glucose than once-daily liraglutide, while rates of severe and gastrointestinal side effects were comparable between the two drugs.

    ⚠What it shows: Credible but slim: only three head-to-head trials with 922 people could be pooled, so the exact size of semaglutide's advantage is still a rough estimate.Meta-analysis · Clin Transl Sci

    Full breakdown →Insulin sensitivity explained →Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials. Clin Transl Sci 2025
22. Metabolic & GLP-1well supported · human dataAdded 1 September 2026

    Workouts do not make you lazier for the rest of the day

    A systematic review of 31 studies found minimal evidence that prescribed exercise makes healthy adults move less during the rest of the day: 100% of randomised trials reported no reduction in non-exercise activity or energy expenditure.

    ⚠What it shows: Reassuringly consistent: a sweep of all the studies on this found 31 relevant papers, and every trial where people were assigned at random showed no drop in day-to-day movement outside workouts. The authors note few studies were purpose-built to test this with gold-standard measurement, so small effects could still have slipped through.Systematic review · Clin Obes

    Full breakdown →Energy balance explained →TDEE Calculator →Does increased prescribed exercise alter non-exercise physical activity/energy expenditure in healthy adults? A systematic review. Clin Obes 2014
23. Metabolic & GLP-1well supported · human dataAdded 1 September 2026

    Lean mass makes up 28% of weight lost on GLP-1 and SGLT2 drugs

    In a meta-analysis of 36 randomised trials, GLP-1 receptor agonists reduced lean body mass by 1.51 kg on average and SGLT2 inhibitors by 1.04 kg, with lean mass accounting for 28% of the total weight lost on these drugs.

    ⚠What it shows: About as solid as this evidence gets: results pooled from 36 trials comparing these drugs with placebo or other treatments, with consistent findings across sexes, conditions and measurement methods. Most participants had obesity or diabetes, and whether the lean tissue lost translates into weaker strength or function was not measured.Meta-analysis · Diabetes Metab Res Rev

    Full breakdown →Sarcopenia explained →Body Fat Calculator →The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Metab Res Rev 2026
24. Metabolic & GLP-1preliminary · human dataAdded 30 August 2026

    Keto beat Mediterranean for the liver, even with identical weight loss

    In a randomised trial of adults with obesity, prediabetes and fatty liver, a matched ~10% weight loss on a very-low-carbohydrate ketogenic diet raised liver insulin sensitivity two to three times more than Mediterranean or very-low-fat diets, and produced the biggest falls in liver fat, glycated haemoglobin and round-the-clock glucose and insulin. LDL cholesterol and apolipoprotein B did not differ between the diets.

    ⚠What it shows: Worth taking seriously but not settled: one trial where adults with obesity plus prediabetes and fatty liver were assigned a diet at random, with weight loss deliberately matched at about 10% across groups. It cannot say whether the liver advantage lasts long term or applies to people without these metabolic problems.Study · Cell Metab

    Full breakdown →Insulin sensitivity explained →Macro Calculator →Effect of diet macronutrient content on the cardiometabolic response to weight loss: A randomized clinical trial. Cell Metab 2026

Back to the full archive · this week’s studies